The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line triplet chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Akihiro Tamiya
No relevant relationships to disclose
Motohiro Tamiya
No relevant relationships to disclose
Takeshi Nakatani
No relevant relationships to disclose
Takayuki Shiroyama
No relevant relationships to disclose
Kanako Kitai
No relevant relationships to disclose
Taisuke Tsuji
No relevant relationships to disclose
Naoko Morishita
No relevant relationships to disclose
Naoki Omachi
Research Funding - AstraZeneca
Kazuhiro Asami
No relevant relationships to disclose
Norio Okamoto
No relevant relationships to disclose
Hidekazu Suzuki
No relevant relationships to disclose
Kyoichi Okishio
No relevant relationships to disclose
Tomoya Kawaguchi
Honoraria - AstraZeneca; Taiho Pharmaceutical
Tomonori Hirashima
No relevant relationships to disclose
Shinji Atagi
Honoraria - Taiho Pharmaceutical